Search Within

Alexander Noor Shoushtari

  1. "Oxford University Press"
Formats
  1. Meeting Abstract (15)
  2. Journal Article (10)
  3. Editorial (2)
  4. Research Letter (1)
  5. Review (1)
Groups
  1. Department of Medicine (29)
  2. Hematologic Malignancies, Division of (29)
  3. Melanoma Disease Management Team (29)
  4. Melanoma and Immunotherapeutics Service (29)
  5. Solid Tumor Oncology Division (29)
  6. Weinberg Fellows (7)

More Groups

People
  1. Michael Postow (6)
  2. Jedd Wolchok (5)
  3. Margaret Callahan (5)
  4. Parisa Momtaz (3)
  5. Paul Chapman (3)
  6. Allison Betof Warner (2)

More People

Years
  1. 2024 (4)
  2. 2023 (5)
  3. 2022 (6)
  4. 2021 (3)
  5. 2020 (5)
  6. 2019 (2)

More Years

Publications
  1. Annals of Oncology (22)
  2. The Oncologist (5)
  3. JNCI: Journal of the National Cancer Institute (1)
  4. Neuro-Oncology (1)
Publishers
  1. Oxford University Press (29)

Results (29)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
    Meeting Abstract

    Betof Warner, A.; Smithy, J. W.; Los, C.; Kalvin, H.; Hasson, N.; Amaria, R. N.; Andrade Czapla, J. A.; Schollenberger, M.; furness, A.; Hassel, J. C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors
    Meeting Abstract

    Cohen, J. V.; Garyantes, T. K.; Muller, C.; Natale, C. A.; Orloff, M.; Patel, S.; Rodon, J.; Shoushtari, A. N.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers
    Meeting Abstract

    Sacco, J. J.; Carvajal, R. D.; Hamid, O.; Kirk, P. B.; Collins, L.; Butler, M. O.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A. P.; Hernandez-Aya, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis
    Journal Article

    Piulats, J. M.; Watkins, C.; Costa-García, M.; del Carpio, L.; Piperno-Neumann, S.; Rutkowski, P.; Hassel, J. C.; Espinosa, E.; de la Cruz-Merino, L.; Ochsenreither, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
    Meeting Abstract

    Shoushtari, A. N.; Middleton, M. R.; Hamid, O.; Meier, F.; Bauer, T.; Salama, A. K. S.; Kirkwood, J. M.; Ascierto, P. A.; Lorigan, P.; Mauch, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
    Meeting Abstract

    Patel, S.; McKean, M.; Piperno-Neumann, S.; Shoushtari, A. N.; Hernandez-Aya, L.; Orloff, M.; Khan, S.; Montazeri, K.; Kapiteijn, E.; Buchbinder, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
    Meeting Abstract

    Orloff, M.; Watkins, C.; Carvajal, R. D.; Shoushtari, A. N.; Sacco, J. J.; Schlaak, M.; Gama, J.; Butler, M. O.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
    Meeting Abstract

    Rodon, J.; Chaney, M. F.; Cohen, J.; Garyantes, T. K.; Ishizuka, J.; Lin, J. J.; Lorusso, P.; Mita, A.; Mita, M.; Muller, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Decision-making and health-related quality of life in patients with melanoma considering adjuvant immunotherapy
    Journal Article

    Atkinson, T. M.; Hay, J. L.; Kim, S. Y.; Schofield, E.; Postow, M. A.; Momtaz, P.; Warner, A. B.; Shoushtari, A. N.; Callahan, M. K.; Wolchok, J. D.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600-or NRAS-mutant melanoma
    Meeting Abstract

    Lebbe, C.; Long, G. V.; Robert, C.; Hamid, O.; Atkinson, V. G.; Shoushtari, A. N.; Daud, A.; Bechter, O. E.; Schadendorf, D.; Sullivan, R. J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save